Developer of orthopaedic bone and joint restoration products gears up international sales division

GAINESVILLE, Fla. -- April 1, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today the appointment of Daniel Berdat as Vice President of International Sales and Marketing, effective April 1.

Berdat, who has previously managed marketing operations in the U.S., China, Philippines and Switzerland, will assume responsibility for more than 30 international markets, including Exactech’s independent distributors and direct operations. Exactech has direct operations in China, Canada, the United Kingdom and Japan. Berdat will be responsible for strategic planning and prioritization of new market entries in all international markets. He will also develop plans for increasing international market penetration.

Exactech President David Petty said, “Daniel’s extensive experience in orthopaedic sales and marketing, strategic planning and broad geographic understanding will further stimulate Exactech’s aggressive international growth. Our international distribution has maintained a five-year compound annual growth rate of more than 22%. In 2008, we expect international sales to be in the $35 million to $40 million range, which represents 22% of our total revenue. We extend an enthusiastic welcome to Daniel as the high level sales and marketing professional that will manage and continue to expand this important part of our business.”

Prior to Berdat’s appointment at Exactech, he was general manager of Plus Orthopedics China, one of the leading domestic reconstructive medical device companies in China. Previously, as the VP of International Sales at Centerpulse (Sulzer Orthopedics), Berdat managed and coordinated sales of orthopaedic products and services, established and maintained distribution channels in Canada and Latin America, and developed new distribution channels in Europe, Asia and Australia.

Berdat also held key management positions with other international orthopaedic companies, including SulzerMedica, where he served as regional sales director for Asia and the Pacific Rim, based in Manila. In previous positions he was responsible for profitability, development and market penetration of countries in Europe, Africa, the Middle East, Australia and New Zealand. He conducted market analysis and opened new markets, establishing subsidiary operations. Earlier he was the Western Europe area manager for a manufacturer and distributor of industrial mechanical components in Switzerland. Berdat has traveled extensively in Australia and the Far East, and speaks several languages. He holds bachelor’s degrees in engineering and economics, and a specialized degree in sales management from the University of St. Gallen, Switzerland. He completed his MBA in the U.S.

About Exactech
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States and Australia, in addition to more than 30 markets in Europe, Asia and Latin America. Additional information about Exactech, Inc. can be found at www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at www.exac.com and www.hawkassociates.com.

An investment profile on Exactech may be found at www.hawkassociates.com/profile/exac.cfm.

Investors may contact Chief Financial Officer Jody Phillips at 352-377-1140 or Julie Marshall or Frank Hawkins, Hawk Associates Inc., at 305-451-1888, e-mail: exactech@hawkassociates.com. To receive future releases in e-mail alerts, sign up at www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

PDF